AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round BioStar Capital led the round with CUE Growth Partners April 04, 2023 07:58 AM ...

AVS began enrolling patients in October 2024 in the POWER PAD II U.S. IDE trial, which is a prospective, single-arm, multi-center study evaluating the technical and clinical success of the PULSE ...

AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., ...

BioStar Capital led the round with CUE Growth Partners. BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial ...